Cargando…
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation
BACKGROUND: Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting with serious, persistent central nervous system adverse events who were foun...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735961/ https://www.ncbi.nlm.nih.gov/pubmed/26831894 http://dx.doi.org/10.1186/s12879-016-1381-x |
_version_ | 1782413179351990272 |
---|---|
author | Pinillos, Francoise Dandara, Collet Swart, Marelize Strehlau, Renate Kuhn, Louise Patel, Faeezah Coovadia, Ashraf Abrams, Elaine |
author_facet | Pinillos, Francoise Dandara, Collet Swart, Marelize Strehlau, Renate Kuhn, Louise Patel, Faeezah Coovadia, Ashraf Abrams, Elaine |
author_sort | Pinillos, Francoise |
collection | PubMed |
description | BACKGROUND: Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism of EFV. None of the children had a CYP2B6 wildtype haplotype. We believe this is the first case of cerebellar dysfunction associated with efavirenz use to be described in children. CASE PRESENTATION: Four black African children, between the ages of 4 and 8 years presenting between 1 and 20 months post-efavirenz initiation, are described. Cerebellar dysfunction, generalised seizures and absence seizures were the range of presenting abnormalities. Plasma efavirenz levels ranged from 20-60 mg/L, 5–15 times the upper limit of the suggested reference range. All abnormal central nervous system manifestations abated after efavirenz discontinuation. CONCLUSION: Efavirenz toxicity should always be considered in human immunodeficiency virus-infected children with unexplained central nervous system abnormalities. Our findings further our understanding of the impact of genetic variants on antiretroviral pharmacokinetics in children across various ethnic groups. Screening for potential EFV-toxicity based on the CYP2B6 c.516 SNP alone, may not be adequate. |
format | Online Article Text |
id | pubmed-4735961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47359612016-02-03 Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation Pinillos, Francoise Dandara, Collet Swart, Marelize Strehlau, Renate Kuhn, Louise Patel, Faeezah Coovadia, Ashraf Abrams, Elaine BMC Infect Dis Case Report BACKGROUND: Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism of EFV. None of the children had a CYP2B6 wildtype haplotype. We believe this is the first case of cerebellar dysfunction associated with efavirenz use to be described in children. CASE PRESENTATION: Four black African children, between the ages of 4 and 8 years presenting between 1 and 20 months post-efavirenz initiation, are described. Cerebellar dysfunction, generalised seizures and absence seizures were the range of presenting abnormalities. Plasma efavirenz levels ranged from 20-60 mg/L, 5–15 times the upper limit of the suggested reference range. All abnormal central nervous system manifestations abated after efavirenz discontinuation. CONCLUSION: Efavirenz toxicity should always be considered in human immunodeficiency virus-infected children with unexplained central nervous system abnormalities. Our findings further our understanding of the impact of genetic variants on antiretroviral pharmacokinetics in children across various ethnic groups. Screening for potential EFV-toxicity based on the CYP2B6 c.516 SNP alone, may not be adequate. BioMed Central 2016-02-02 /pmc/articles/PMC4735961/ /pubmed/26831894 http://dx.doi.org/10.1186/s12879-016-1381-x Text en © Pinillos et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Pinillos, Francoise Dandara, Collet Swart, Marelize Strehlau, Renate Kuhn, Louise Patel, Faeezah Coovadia, Ashraf Abrams, Elaine Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title_full | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title_fullStr | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title_full_unstemmed | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title_short | Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation |
title_sort | case report: severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of cyp2b6 genetic variation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735961/ https://www.ncbi.nlm.nih.gov/pubmed/26831894 http://dx.doi.org/10.1186/s12879-016-1381-x |
work_keys_str_mv | AT pinillosfrancoise casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT dandaracollet casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT swartmarelize casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT strehlaurenate casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT kuhnlouise casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT patelfaeezah casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT coovadiaashraf casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation AT abramselaine casereportseverecentralnervoussystemmanifestationsassociatedwithaberrantefavirenzmetabolisminchildrentheroleofcyp2b6geneticvariation |